+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

In Vitro Diagnostics Business Outlook, 2024 (6 updates)

  • Report

  • 33 Pages
  • January 2024
  • Region: Global
  • Kalorama Information
  • ID: 5930709

In Vitro Diagnostics Business Outlook is a bimonthly publication with six issues annually. 

In Vitro Diagnostics Business Outlook offers information and data that you cannot get anywhere else, including: 

  • Market data and forecasts (growth rates, market size, market share, etc.) to identify growth opportunities
  • A comprehensive view of the IVD market with test categories covered and company briefs
  • M&A activities, selected partnerships & collaborations, partnership deals, and more
  • Industry & region watch to help tailor strategies
  • Analysis of news and events and reporting on news not easily available 

Table of Contents

Market Analysis: Molecular HLA/Transplant Testing
  • Overview of Molecular HLA/Transplant Testing
  • Market Outlook
  • Regional Market
  • Top Company Briefs
  • Immucor
  • Luminex/Diasorin
  • Caredx
  • Thermo Fisher Scientific
Executive News Briefing
  • Dekfi Diagnostics Appoint New CEO
  • Onera Raises $32 Million in Funding
  • Cleveland Diagnostics Completes $75 Million in Funding
Financial Highlights: Agilent and Hologic
  • Agilent Full Year Fiscal 2023 Sales Up 1.5% in Core Business YOY
  • Figure: Agilent Sales, by Business (Agilent Crosslab Group, Diagnostics and Genomics Group, Life Sciences and Applied Markets Group), Fy 2022 and Fy 2023
  • Figure: Agilent Sales, by Business (Agilent Crosslab Group, Diagnostics and Genomics Group, Life Sciences and Applied Markets Group), Fy 2023 Quarterly Performance
  • Table: Agilent Revenue Mix, by Type (Consumables/Services/Informatics and Instruments), Fy 2023 (%)
  • Figure: Agilent Fy 2023 Regional Sales Breakdown Distribution, by Region (Americas, Asia-Pacific, Europe) (%)
  • Hologic Supports Strong Financial Performance in Full-Year Fiscal Year Guidance
  • Table: Hologic Diagnostic Sales Performance, by Product Group (Blood Screening, Cytology & Perinatal, Molecular Diagnostics), Fy 2023 ($ Millions)
  • Figure: Hologic Revenue, by Product Group (Blood Screening, Cytology & Perinatal, Molecular Diagnostics), Fy 2022 and Fy 2023 ($ Millions)
  • Figure: Hologic Geographic Revenue Distribution, by Region (Asia-Pacific, Europe, United States, All Others), Fy 2023 (%)
Diagnostic Market Mergers, Acquisitions, and Partnership Deals
  • Mergers and Acquisitions
  • Table: Selected Diagnostic Market Mergers and Acquisitions Deals
  • Partnerships and Collaborations
Industry Watch
  • COVID-19 Update
Region Watch
  • India
  • Figure: India Real GDP Growth, Inflation Rate (Consumer Prices), 2017-2024
  • Figure: India Ivd Market Distribution of Sales, by Broad Ivd Segment (Chemistry/Hematology/Coagulation, Histology/Cytology, Immunoassays, Microbiology/Virology, Point-Of-Care Glucose, Other Segments), 2023 (%)
  • Saudi Arabia
  • Figure: Saudi Arabia Population Pyramid, 2023 and 2053
  • Figure: Saudi Arabia Total Annual Liquid Fuels Production and Consumption, 2013-2022 (Millions of Barrels)
  • Figure: Saudi Arabia Ivd Market Share, by Broad Ivd Segment (Chemistry/Hematology/Coagulation, Histology/Cytology, Immunoassays, Microbiology/Virology, Point-Of-Care Glucose, Other Segments), 2023
Broad-based Company Announcements
  • Quidelortho Obtains FDA Nod
  • Illumina Plans to Divest Grail
  • Roche to Acquire Lumiradx
  • Qiagen Expands Footprint with New Regional Headquarters in Middle East

Companies Mentioned

  • Agilent
  • CareDx
  • Cleveland Diagnostics
  • DEKFI Diagnostics
  • Illumina
  • Immucor
  • Luminex/DiaSorin
  • LumiraDx
  • Onera
  • QIAGEN
  • QuidelOrtho
  • Roche
  • Thermo Fisher Scientific